Cargando…
The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
INTRODUCTION: Bortezomib has been reported to favourably impact the outcomes of t(4;14) and del(17p) in multiple myeloma (MM), but its impact on gain 1q (+1q) is unknown. METHODS: To address this, 250 patients treated with bortezomib-based induction were analysed. All myeloma samples had fluorescenc...
Autores principales: | Tang, Hoi Ki Karen, Fung, Chi Yeung, Morgan, Gareth J., Kumar, Shaji, Siu, Lisa, Ip, Ho Wan Alvin, Yip, Sze Fai, Lau, Ka Ngai Harry, Lau, Chi Kuen, Lee, Harold, Leung, Kwan Hung, Kho, Bonnie, Wong, Howard, Ngai, Cheong, Hwang, Yu Yan, Sim, Joycelyn, Kwong, Yok Lam, Chim, Chor Sang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019371/ https://www.ncbi.nlm.nih.gov/pubmed/35465644 http://dx.doi.org/10.1177/20406207221082043 |
Ejemplares similares
-
Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD
por: Chim, Chor Sang, et al.
Publicado: (2012) -
Case series: MRD negativity assessment using (11)C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma
por: Ngai, Cheong, et al.
Publicado: (2021) -
Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NFκB pathway
por: Wang, Lu Qian, et al.
Publicado: (2013) -
Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia
por: Wang, Lu Qian, et al.
Publicado: (2014) -
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
por: Wong, Kwan Yeung, et al.
Publicado: (2013)